USFDA pulls up Glenmark for manufacturing lapses at Pithampur plant
In a warning letter, the US Food and Drug Administration (USFDA) also pointed out the company's failure to follow an adequate written testing programme at the facility to assess stability characteristics of drug products.
The USFDA inspected the Pithampur, Madhya Pradesh-based manufacturing plant from February 3-14, 2025.
A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations.
'This warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals," it stated.
'Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," it added.
Elaborating on the issues at the facility, USFDA stated that the firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed.
'Your firm failed to follow an adequate written testing program designed to assess the stability characteristics of drug products," it added.
'Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labelling, and drug products conform to appropriate standards of identity, strength, quality, and purity," USFDA noted.
USFDA stated that it has cited similar CGMP violations at the company's other facilities in Himachal Pradesh, Goa and the US, as well.
'These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate," USFDA said.
The US health regulator asked the drug firm to engage a consultant to assist in meeting CGMP requirements.
It further said, 'Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP." Failure to address any violations may also result in FDA continuing to refuse admission of articles manufactured at the plant, it added. PTI MSS MSS SHW
view comments
First Published:
July 23, 2025, 19:15 IST
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
26 minutes ago
- Hindustan Times
'India NOT reviewing list of US goods exempted from tariffs': MEA debunks fake reports
Amid the tariff row between the United States and India, the Ministry of External Affairs has debunked certain fake reports circulating on social media. Taking to X, the fact check unit of the ministry has dismissed reports that India is reviewing US goods exempted from tariffs as it works towards a response to Trump's 25 percent bombshell on New Delhi. US president Donald Trump announced 25 percent tariffs on "good friend" India last week. The tariffs for India come with a penalty due to its participation in BRICS and trade with Russia,(PTI) In another post, the fact check unit for MEA dismissed a report which claimed that India is reviewing its bilateral agreements with the United States and considering suspending them 'if hostile economic policies continue.' This is a developing story…
Mint
26 minutes ago
- Mint
ED arrests ex-Axis Mutual Fund manager in 'front-running' case
The Enforcement Directorate (ED) has arrested Viresh Joshi, a former chief trader and fund manager of Axis Mutual Fund, in connection with a 'front-running' case involving alleged cheating of investors to the tune of ₹ 200 crore. Joshi was taken into custody on Saturday under the anti-money laundering law and has been remanded to ED custody until August 8 by a special Prevention of Money Laundering Act (PMLA) court, reported PTI. The case of front-running involves unethical and illegal practice in the securities market in which brokers or traders execute orders for their personal benefit by using advance knowledge of pending client orders. This malpractice undermines market integrity and puts other investors at a disadvantage. The federal probe agency's investigation stems from an FIR registered by the Mumbai Police in December 2024, alleging that Joshi, while serving as a fund manager at Axis Mutual Fund, "exploited" confidential information on the trades to be executed on behalf of the fund house. He is accused of pre-emptively trading stocks to generate substantial "illicit" gains, thereby cheating the investors of Axis Mutual Fund, which holds assets under management of more than ₹ 2 lakh crore, the ED told PTI. The ED launched searches in the case on August 1, across multiple locations in Delhi, Mumbai, Gurugram, Ludhiana, Ahmedabad, Bhavnagar, Bhuj and Kolkata. The agency stated that, "the search operations were part of an ongoing investigation into the illegal profits made by certain entities/persons by indulging in front-running trade activities in scrips traded by Axis Mutual Fund from 2018 to 2021.' According to ED, "The accused had utilised a terminal in Dubai to punch the front-running trade orders through mule trading accounts obtained from various brokers. Other than the case involving Joshi, the investigation has further revealed that many other traders/brokers have also misused the advance inputs on Axis Mutual Fund trades to indulge in front-running, generating illicit trade profits, which are deemed 'nothing but proceeds of crime," the agency alleged. The agency estimates the illicit funds generated by various traders/brokers to exceed ₹ 200 crore, with potential for this sum to be much higher, according to a news report.
News18
36 minutes ago
- News18
Air India cancels Singapore-Chennai flight due to technical issue
Last Updated: New Delhi, Aug 3 (PTI) Air India on Sunday cancelled its flight from Singapore to Chennai due to a technical issue. The flight AI349 was to be operated with an Airbus A321. In a statement on Sunday, the airline said the flight AI349 scheduled to operate from Singapore to Chennai has been cancelled due to a maintenance task identified prior to departure which required additional time for rectification. 'Arrangements are being made to fly the passengers to Chennai at the earliest. Hotel accommodation is being provided, and full refunds on cancellation, or complimentary rescheduling is also being offered to passengers based on their preference," Air India said. According to the airline, ground colleagues in Singapore are making every possible effort to minimise the inconvenience caused to the passengers due to this unforeseen disruption. view comments First Published: August 03, 2025, 19:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
